Physician profile
Stephen E Halpin
NPI 1346229937
$1,590.55
in general payments reported to CMS, 2019-2025
12 companies · $96.62 in 2025
The $96.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $39.89 · 2021: $496 · 2022: $144 · 2023: $148 · 2024: $146 · 2025: $96.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.79 | 2019-2022 | |
| Harmony Biosciences LLC | $249.98 | 2021-2022 | |
| Novo Nordisk INC | $172.61 | 2019-2021 | |
| Abbvie INC. | $137.63 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Glassia |
| Sk Life Science, INC. | $96.62 | 2025 | |
| Pfizer INC. | $91.12 | 2019-2020 | |
| Allergan, INC. | $76.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.17 | 2019 | |
| Astellas Pharma US INC | $22.73 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Halpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.